The stock value of Kazia Therapeutics Limited (NASDAQ: KZIA) had a significant increase in the most recent trading session, rising 92.19% to $10.10. This notable increase came after promising preclinical findings were published in the prestigious journal Molecular Cancer Therapeutics, which is affiliated with the American Association for Cancer Research.
Paxalisib Could Revolutionize TNBC’s Business
The recently released research focuses on the potential of paxalisib, Kazia’s primary experimental medicine, to transform the management of triple-negative breast cancer (TNBC), a highly aggressive and resistant cancer subtype.
The study, which is headed by Professor Sudha Rao of the QIMR Berghofer Medical Research Institute, demonstrates how paxalisib can improve immune responses and change the tumor microenvironment. The medication showed synergistic anti-cancer benefits when used in conjunction with immune checkpoint inhibitors, which is encouraging as these immunotherapies become more popular in oncology.
Combined Therapeutic Potential and Mechanistic Understanding
One of the study’s main conclusions is that, in comparison to PI3K inhibition alone, combined inhibition of the PI3K and mTOR pathways is more effective at preventing tumor development and cell migration. Additionally, paxalisib was demonstrated to enhance CD4+ and CD8+ T cell infiltration and activation within TNBC tumors, highlighting its promise in immune-based cancer treatments.
Paxalisib and pembrolizumab (KEYTRUDA) together decreased tumor burden and increased survival rates in preclinical animals, confirming the usefulness of this combination therapy approach.
Advancements in Clinical Use
These results have set the stage for Kazia’s newly launched Phase 1b clinical study, which will assess paxalisib in patients with advanced breast cancer in conjunction with checkpoint inhibitors and chemotherapy. An important step in converting preclinical promise into clinical benefit is this experiment.
According to Kazia, this result enhances paxalisib’s therapeutic potential beyond brain malignancies and places it as a top contender for next-generation immunotherapy for solid tumors.
“Combination of the PI3K/mTOR inhibitor paxalisib with immune checkpoint inhibitors enhances antitumor activity in preclinical models of triple-negative breast cancer,” states the study, which provides a strong basis for additional clinical investigation.
